drugset / Trial / NCT01092546

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

NCT01092546

Phase 3 Terminated 12 enrolled GE Healthcare i3 Statprobe · collab
NaSingle-groupOpen-labelDiagnostic

Summary

To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

Timeline

Start
2010-03
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Flutemetamol Diagnostic / imaging agent 10 mg Intravenous
Subject Flutemetamol Diagnostic / imaging agent 185 mbq Intravenous